Metabolic and cardiovascular side-effects of modern antipsychotic drugs;Metabolske og kardiovaskulære bivirkninger av moderne antipsykotika

Tidsskrift for den Norske Laegeforening

Volumn 124, Issue 2, 2004, Pages 181-182

  Andreassen, Ole A ^a   Bentsen, Håvard ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

BODY WEIGHT DISORDER; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; METABOLIC DISORDER; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; SHORT SURVEY; THROMBOEMBOLISM; WEIGHT GAIN; ARTICLE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; RISK FACTOR;

ANTIPSYCHOTIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERLIPIDEMIAS; RISK FACTORS; WEIGHT GAIN;

EID: 1442285315     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (21)

1. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-7.
2. Druss BG, Bradford WD, Rosenheck RA, Radford MJ, Krumholz HM. Quality of medical care and excess mortality in older patients with mental disorders. Arch Gen Psychiatry 2001; 58: 565-72.
3. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001; 58: 1161-7.
4. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
5. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60: 358-63.
6. Russell JM, Mackell JA. Body weight gain associated with atypical antipsychotics. Epidemiology and therapeutic implications. CNS Drugs 2001; 15: 537-51.
7. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369-74.
8. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021.
9. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325: 243.
10. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-6.
11. Lindenmayer J-P, Czobor P, Volavka J, Citrome L, Sheitman B, McEnvoy JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-6.
12. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002; 59: 337-45.
13. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003; 107: 85-95.
14. Feinstein RE. Cardiovascular effects of novel antipsychotic medications. Heart Dis 2002; 4: 184-90.
15. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. Thioridazine and sudden unexplained death in psychiatric in-patients. Br J Psychiatry 2002; 180: 515-22.
16. Hagg S, Spigset O, Bate A, Söderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21: 382-8.
17. Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322: 1207-9.
18. Roesch-Ely D, Van Einsiedel R, Kathofer S, Schwaninger M, Weisbrod M.Myocarditis with quetiapine. Am J Psychiatry 2002; 159: 1607-8.
19. Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs 2002; 16: 765-76.
20. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A et al. International Suicide Prevention Trial Study Group. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91.
21. Czobor P, Volavka J, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J et al. Antipsychotic-induced weight gain and therapeutic response: a differential association. J Clin Psychopharmacol 2002;22:244-51.